<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="16327">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02894333</url>
  </required_header>
  <id_info>
    <org_study_id>JBL_2014-30</org_study_id>
    <nct_id>NCT02894333</nct_id>
  </id_info>
  <brief_title>Action-effect Anticipation in Patients With Parkinson's Disease : A Study of the Sensory Attenuation Marker.</brief_title>
  <acronym>IDEOMOT</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <brief_summary>
    <textblock>
      The ideomotor theory of action control is considered to be central to the understanding of
      human voluntary action. According to the ideomotor theory, an action is represented in terms
      of its desired sensory effects and actions are selected by internally activating these
      effect representations. Recent imagery and behavioral studies showed that this anticipated
      representation of action-effects triggered a &quot;sensory attenuation&quot;, meaning a decrease of
      perceptive performances or a decrease of sensory event-related potentials (ERP) for an
      expected event. Thus, the sensory attenuation constitutes a relevant behavioral tool to
      investigate sensory anticipation impairment in patients with Parkinson's disease. In a
      behavioral paradigm, patients and matched control participants have to perform a perceptive
      task on predicted visual action-effects mixed with mispredicted visual action effects.
      Performances should be better in mispredicted visual action effects for control participants
      only.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>median score</measure>
    <time_frame>baseline</time_frame>
    <description>scores measured with the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS)</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Patients with Parkinson's disease</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>behavioral observation</intervention_name>
    <arm_group_label>Patients with Parkinson's disease</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with Parkinson's disease
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Parkinson's disease

          -  Normal or corrected vision

        Exclusion Criteria:

          -  Other pathology or neurological or psychiatric history

          -  Known pregnancy or breastfeeding

          -  Absence of affiliation to the French Social Security

          -  Person under legal protection

          -  Patient's opposition to participate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Laurence Salomon, MD</last_name>
    <phone>+33 1 48 03 64 31</phone>
    <email>lsalomon@fo-rothschild.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fondation Ophtalmologique Adolphe de Rothschild</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fondation Ophtalmologique Adolphe de Rothschild</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurence Salomon, MD</last_name>
      <phone>+33 1 48 03 64 31</phone>
      <email>lsalomon@fo-rothschild.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Philippe Brandel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>September 5, 2016</lastchanged_date>
  <firstreceived_date>September 5, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson's disease</keyword>
  <keyword>Action-effect prediction</keyword>
  <keyword>Sensory attenuation</keyword>
  <keyword>Voluntary action</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
